CareDx Inc (CDNA)vsDanaher Corporation (DHR)
CDNA
CareDx Inc
$79.81
-1.68%
HEALTHCARE · Cap: $4.59B
DHR
Danaher Corporation
$232.17
-1.34%
HEALTHCARE · Cap: $163.25B
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 5048% more annual revenue ($25.61B vs $497.40M). CDNA leads profitability with a 25.9% profit margin vs 16.9%. CDNA trades at a lower P/E of 36.9x. DHR earns a higher WallStSmart Score of 65/100 (B-).
CDNA
Buy60
out of 100
Grade: C
DHR
Strong Buy65
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+70.0%
Fair Value
$65.83
Current Price
$79.81
$13.98 discount
Margin of Safety
-87.8%
Fair Value
$122.57
Current Price
$232.16
$109.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 39.3% year-over-year
Earnings expanding 1067.0% YoY
Conservative balance sheet, low leverage
Keeps 26 of every $100 in revenue as profit
Large-cap with strong market position
Strong operational efficiency at 21.1%
Earnings expanding 37.8% YoY
Generating 1.6B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Trading at 9.0x book value
ROE of -2.6% — below average capital efficiency
Distress zone — elevated risk
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : CDNA
The strongest argument for CDNA centers on Revenue Growth, EPS Growth, Debt/Equity. Profitability is solid with margins at 25.9% and operating margin at 8.5%. Revenue growth of 39.3% demonstrates continued momentum.
Bull Case : DHR
The strongest argument for DHR centers on Market Cap, Operating Margin, EPS Growth. Profitability is solid with margins at 16.9% and operating margin at 21.1%. PEG of 1.32 suggests the stock is reasonably priced for its growth.
Bear Case : CDNA
The primary concerns for CDNA are P/E Ratio, Price/Book, Return on Equity.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio.
Key Dynamics to Monitor
CDNA profiles as a growth stock while DHR is a mature play — different risk/reward profiles.
CDNA carries more volatility with a beta of 2.38 — expect wider price swings.
CDNA is growing revenue faster at 39.3% — sustainability is the question.
DHR generates stronger free cash flow (1.6B), providing more financial flexibility.
Bottom Line
DHR scores higher overall (65/100 vs 60/100), backed by strong 16.9% margins. CDNA offers better value entry with a 70.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CareDx Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?